Neuromodulation for Depression: Evidence by Technique
Brain stimulation techniques for depression compared one by one, from ECT and TMS to implanted and home devices, with the evidence level and FDA status read for each.
Content last updated . This page has not been medically reviewed.
If you or someone you know is in crisis
If you or someone you know is struggling or having thoughts of suicide, call or text the 988 Suicide and Crisis Lifeline at 988 (United States). [1] In a life-threatening situation, call 911. [1]The short version
"Neuromodulation" for depression means using electricity or magnets to change brain activity. The techniques are not interchangeable. They differ in how invasive they are, how strong the evidence is and what the FDA has authorized. NIMH says these therapies are usually used after other treatments have been tried, should be prescribed and monitored by a trained provider, and that people should not stop a treatment unless a health care provider advises it. [1] This page is information only, not medical advice.Evidence labels: established (several well-run human studies agree), promising but limited, mixed, insufficient evidence. See how we label evidence.
Technique by technique
| Technique | FDA status (US, as read 2026-10-22) | Evidence | Main risks |
|---|---|---|---|
| Electroconvulsive therapy (ECT) | Cleared for severe depressive episodes in people 13 and older with depression or bipolar disorder. [1] | Established. In a 2022 umbrella review of meta-analyses, ECT beat sham with a standardized effect of 0.91 (moderate certainty). [2] | Memory loss and confusion, more with bilateral electrode placement. [1] |
| Repetitive TMS (rTMS), including theta burst | The first device was cleared in 2008 for people who did not respond to at least one antidepressant in the current episode. [1] In March 2024 the FDA cleared rTMS as adjunctive treatment in adolescents 15 and older. [1] | Established for treatment-resistant depression: NIMH says strong clinical evidence supports reducing symptoms. [1] Effect 0.51 versus sham (moderate certainty). [2] | Scalp discomfort and headache; seizure risk is low. [1] |
| Vagus nerve stimulation (implanted) | Approved in 2005 for long-lasting, severe or recurrent depression that has not eased after at least four other treatments. [1] | Mixed. NIMH says study results have been mixed. [1] | Surgery risks, voice changes, hoarseness. [1] |
| tDCS (weak direct current) | One home headset, the Flow FL-100, was approved by premarket approval on 2025-12-08 for moderate to severe depression, alone or as adjunct, in adults not considered treatment refractory to medication. [3] | Promising but limited. A trial found it was not shown noninferior to escitalopram; both beat placebo. [4] | In that trial, skin redness, tinnitus and nervousness were more frequent with tDCS, and 2 people had new-onset mania. [4] |
| Deep brain stimulation (DBS) | NIMH lists it among therapies still considered experimental and not yet authorized by the FDA for mental disorders. [1] | Insufficient to mixed. Effect 0.42 (very low certainty) in the umbrella review. [2] | Brain surgery to implant electrodes. [1] |
| Magnetic seizure therapy | In the US it is available only in clinical trials. [1] | Insufficient evidence | Like ECT, it is done under anesthesia with a muscle relaxant. [1] |
| Cranial electrical stimulation | See that page. | Insufficient evidence for depression [5] |
An approval of one device does not generalize. The tDCS approval above names one product and its stated indication; I did not read the clinical summary behind it, and other tDCS devices sold online have separate (or no) regulatory records. See device-specific approval for brain stimulation.
Comparing techniques
ECT versus magnets. A network meta-analysis of 113 randomized trials (6,750 patients) found that 10 of 18 strategies produced more response than sham. [6] Examples: bitemporal ECT (odds ratio 8.91, 95% CI 2.57 to 30.91), high-frequency left rTMS (3.17, 2.29 to 4.37) and tDCS (2.65, 1.55 to 4.55). [6] Among active treatments, bitemporal ECT and high-dose right unilateral ECT were linked to more response. [6] NIMH likewise says rTMS does not match the therapeutic effects of ECT. [1] Effects are relative to sham, and wide confidence intervals mean the exact ranking is uncertain.Which rTMS style. In a randomized non-inferiority trial, a shorter theta burst form was non-inferior to standard high-frequency rTMS for treatment-resistant depression, with headache the most common adverse event in both groups. [7]
ECT speed and follow-up. NIMH says ECT often works within the first week of treatment, and that follow-up treatment is usually needed to keep the benefit. [1]
ECT versus medication. An older systematic review found ECT significantly more effective than simulated ECT, and more effective than drug therapy. [8]
Mixed and negative findings
- tDCS versus escitalopram: noninferiority could not be claimed, and more adverse events occurred with tDCS in that single-center trial. [4]
- Deep brain stimulation: a 2026 randomized trial (35 people) found no significant differences among stimulation groups during the blinded phase. [9] Most participants later met response criteria in the open-label phase (65.7% to 73.1%), but open-label results have no sham comparison. [9]
- Low-intensity focused ultrasound: a small pilot study showed some early mood effects but only non-significant trends in the full analysis. [10] See focused ultrasound.
Who should talk with a clinician first
Anyone considering these treatments needs a full psychiatric and medical assessment, since brain stimulation is for serious depression and is delivered by trained teams. [1] Seizure history, implanted devices and a history of mania or bipolar disorder can change the risks; in the main tDCS trial, 2 people developed new-onset mania. [4] See brain stimulation contraindications and seizure considerations, psychiatric context and home-use claims and DIY brain stimulation risks.Related guides
Transcranial magnetic stimulation, vagus nerve stimulation, tDCS and tACS research, treatment-resistant depression with psilocybin and ketamine and stress, anxiety, burnout and depression.Frequently asked questions
Is TMS better than ECT?
ECT showed higher response in a large network meta-analysis, and NIMH says rTMS does not match ECT's effects. [6][1] ECT also carries memory side effects, so the choice depends on severity, history and preference. [1]
Does the FDA approve home brain stimulation for depression?
For one product, yes: the FDA approved the Flow FL-100 headset in December 2025 for a stated indication. [3] That does not extend to other home devices. I did not verify other products.
How long do effects last?
ECT usually needs follow-up treatment to sustain improvement. [1] Long-term safety of rTMS has not been determined. [1]
Is tDCS as good as an antidepressant?
In the main trial it was not shown to be noninferior to escitalopram, though both beat placebo. [4]
Is deep brain stimulation an option?
NIMH describes it as experimental for mental disorders in the sense of FDA authorization, used for severe treatment-resistant cases. [1] A randomized trial found no significant group differences in the blinded phase. [9]
What are the main risks?
They vary: memory and confusion with ECT, scalp discomfort with rTMS, surgery risks with implants. [1]
References
- National Institute of Mental Health. Brain Stimulation Therapies. Read 2026-10-22.
- Rosson et al. Brain stimulation and other biological non-pharmacological interventions in mental disorders: An umbrella review. Neuroscience and biobehavioral reviews, 2022. Read 2026-10-22.
- U.S. Food and Drug Administration, openFDA device PMA record P230024 (Flow FL-100). Read 2026-10-22.
- Brunoni et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. The New England journal of medicine, 2017. Read 2026-10-22.
- Kavirajan et al. Alternating current cranial electrotherapy stimulation (CES) for depression. The Cochrane database of systematic reviews, 2014. Read 2026-10-22.
- Mutz et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2019. Read 2026-10-22.
- Blumberger et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet (London, England), 2018. Read 2026-10-22.
- Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet (London, England), 2003. Read 2026-10-22.
- Giacobbe et al. Deep Brain Stimulation to the Subgenual Cingulate Gyrus for Treatment-Resistant Depression: A Randomized Controlled Trial and 2-Year Long-Term Follow-Up: Stimulation cérébrale profonde du gyrus cingulaire subgénual pour traiter la dépression résistante au traitement : Essai contrôlé à répartition aléatoire et suivi à long terme sur deux ans. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2026. Read 2026-10-22.
- Riis et al. Noninvasive Modulation of the Subcallosal Cingulate and Depression With Focused Ultrasonic Waves. Biological psychiatry, 2025. Read 2026-10-22.